CDKN2A and central nervous system cancer: Using SSCP and qPCR, Barker et al. (1997) analysed 42 gliomas (16 glioblastomas [5 recurrent], 15 anaplastic astrocytomas [4 recurrent], and 11 astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas [1 recurrent]) and found a higher incidence of CDKN2A HD in higher vs. lower grade tumours (80% vs. 20%, p = 0.001).